A methotrexate (MTX) -resistant colorectal cancer cell line HT-29 (HT-29-R) has been developed. H19 was upregulated in HT-29-R cells. H19 mediated MTX resistance in colorectal cancer (CRC). Wnt/β-catenin pathway was involved in the H19-mediated MTX resistance in CRC cells.